Unigestion Holding SA Grows Stake in Cencora, Inc. (NYSE:COR)

Unigestion Holding SA increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 19.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 153,290 shares of the company's stock after purchasing an additional 25,470 shares during the quarter. Cencora makes up about 2.5% of Unigestion Holding SA's investment portfolio, making the stock its 11th largest holding. Unigestion Holding SA owned about 0.08% of Cencora worth $42,619,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JFS Wealth Advisors LLC raised its stake in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the last quarter. Banque Transatlantique SA bought a new stake in shares of Cencora in the fourth quarter worth $29,000. SBI Securities Co. Ltd. purchased a new stake in Cencora during the fourth quarter valued at $30,000. Kentucky Trust Co purchased a new stake in Cencora in the fourth quarter worth about $33,000. Finally, WASHINGTON TRUST Co grew its position in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares of the company's stock, valued at $3,934,326.20. This represents a 21.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 40,253 shares of company stock valued at $11,102,417. Insiders own 10.80% of the company's stock.

Cencora Trading Down 0.4%

Shares of NYSE:COR traded down $1.11 during trading on Thursday, hitting $287.91. The company had a trading volume of 1,190,019 shares, compared to its average volume of 1,531,521. The stock has a market cap of $55.80 billion, a price-to-earnings ratio of 40.95, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The company has a fifty day simple moving average of $285.86 and a two-hundred day simple moving average of $259.51. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the company earned $3.80 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's payout ratio is 25.52%.

Wall Street Analyst Weigh In

COR has been the subject of several research analyst reports. Robert W. Baird increased their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Citigroup increased their target price on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Finally, Bank of America raised their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.